Using Regenerative Medicine for Meniscus Relief

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, October 13, 2022

Although there are an average of 700,000 meniscus surgeries per year, there is a 20-40 percent failure rate. But this company is working on using regenerative procedures and has just completed an important step.

Clinical-stage regenerative medicine company, ChitogenX Inc., (CSE: CHGX) announced in a press release today the launch of its second orthopedic development program in meniscus repair following the development completion of its preclinical arthroscopic surgery program. ChitogenX focuses on the development of novel tissue repair regenerative technologies.

The preclinical meniscus repair trial and surgeries to begin in November 2022 and the completion of preclinical arthroscopic surgery procedure represents key milestone for meniscus repair development program. The surgeries are expected to be completed by the end of November with study results expected fall of 2023.

Shares closed Wednesday trade at $0.23.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.